The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Adcetris® (brentuximab vedotin) approved by Health Canada as post-ASCT consolidation treatment of Hodgkin Lymphoma (HL)
On 25th July 2017, Health Canada granted a non-conditional marketing authorization to Adcetris® (Brentuximab Vedotin; BV), an antibody-drug conjugate directed against CD30, as consolidation post-Autologous Stem Cell Transplant (ASCT) for patients with Hodgkin Lymphoma (HL) at increased risk of relapse or progression.1
This decision was made based on results from the randomized phase III AETHERA trial (NCT01100502), which aimed to assess the efficacy and safety of BV and best supportive care versus placebo and best supportive care in patients with high risk of residual HL after ASCT. In 2015, Prof. Craig Moskowitz from the Memorial Sloan Kettering Cancer Center, New York, NY, USA, et al. published findings from the trial in the Lancet:2
Key Highlights:
- Patients enrolled = 329 patients; patients were randomly assigned to BV (n=165) or the placebo (n=164)
- PFS by independent review was significantly improved with BV versus placebo (HR, 0.57; 95% CI, 0.40–0.81; P = 0.0013)
- Median PFS by independent review for BV patients was 42.9 months (95% CI, 30.4–42.9) versus 1 months (95% CI, 11.5–not estimable) for placebo patients
- Consistent benefit (HR <1) of BV consolidation observed across subgroups
- The most frequent AEs with BV and placebo were peripheral sensory neuropathy (94/167 [56%] vs 25/160 [16%]) and neutropenia (35% vs 12%)
- At time of analysis, 28/167 (17%) patients had died in the BV arm versus 25/160 (16%) in the placebo arm
Previously in 2013, Adcetris® was granted conditional marketing authorization by Health Canada for two lymphoma indications: HL patients who relapse after ASCT or in patients ineligible for ASCT who experience relapse after ≥2 multi-agent chemotherapy regimens; and for systemic Anaplastic Large Cell Lymphoma (sALCL) patients who relapse after ≥1 multi-agent chemotherapy regimen.1
Currently, BV is being evaluated in a number of phase III clinical trials including the ECHELON-1 (NCT01712490) and ECHELON-2 (NCT01777152) trials in frontline classical HL and frontline mature T-Cell Lymphomas, respectively, as well as the recently initiated CheckMate 812 trial of BV plus nivolumab in relapsed/refractory HL (NCT03138499).
Furthermore, the randomized, open-label, phase III ALCANZA trial (NCT01578499) of BV compared to investigator’s choice (methotrexate or bexarotene) in patients with CD30+ Cutaneous T-Cell Lymphoma was recently completed – read more here or watch our interview with Prof. Miles Prince from the Peter MacCallum Cancer Center, Melbourne, AUS, on the trial’s final results at ICML 2017.
References